Key result
Cardiac resynchronization therapy was cost-effective compared to optimal pharmacological treatment, with the cost per QALY gained ranging from 3600 euros to 6700 euros across the Nordic region.
Why the study?
Is cardiac resynchronization therapy cost-effective compared to optimal pharmacological treatment in patients with moderate to severe heart failure and dyssynchrony?
Population
813 patients with moderate to severe heart failure with markers of cardiac dyssynchrony
Comparison
Cardiac resynchronization therapy added to… vs Optimal pharmacological treatment alone
Design
Other, randomised
Follow-up
average 29.4 months
Authors
Loading...
Supports CRT adoption in Nordic HF settings; leaves open generalizability beyond modeled data.
RCT (n=813)
Yes
Is cardiac resynchronization therapy cost-effective compared to optimal pharmacological treatment in patients with moderate to severe heart failure and dyssynchrony?
Cardiac resynchronization therapy is a cost-effective treatment in Scandinavian health care settings for patients with moderate to severe heart failure and dyssynchrony.
Blomström et al. (2008) conducted an RCT in Moderate to severe heart failure with markers of cardiac dyssynchrony (n=813). Cardiac resynchronization therapy (CRT) vs. Optimal pharmacological treatment was evaluated on Cost-effectiveness ratio per quality-adjusted life year (QALY) gained (95% CI 1169-17482). Cardiac resynchronization therapy was cost-effective compared to optimal pharmacological treatment, with the cost per QALY gained ranging from 3600 euros to 6700 euros across the Nordic region.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: